NCT03988530 is a Phase 3 clinical trial of Scopolamine in Motion Sickness, sponsored by Repurposed Therapeutics, Inc..

Who is sponsoring NCT03988530?

NCT03988530 is sponsored by Repurposed Therapeutics, Inc..

What drugs are being tested in NCT03988530?

Interventions in NCT03988530: Scopolamine, Placebo Nasal Gel.

What condition does NCT03988530 study?

NCT03988530 studies Motion Sickness.

Is NCT03988530 still recruiting?

NCT03988530 is currently completed. Last updated 6 May 2023.

Last reviewed 2023-05-06 · How we verify

NCT03988530

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

Completed Phase 3 Last updated 6 May 2023

What this trial tests

Phase 3 trial testing Scopolamine in Motion Sickness in 98 participants. Completed in 23 November 2020.

Timeline

7 June 2019

Primary endpoint
23 November 2020

23 November 2020

Quick facts

Lead sponsor	Repurposed Therapeutics, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	98
Start date	7 June 2019
Primary completion	23 November 2020
Estimated completion	23 November 2020
Sites	1 location across United States

Drugs / interventions tested

Scopolamine — full drug profile →
Placebo Nasal Gel

Conditions studied

Motion Sickness — all drugs for Motion Sickness →

Sponsor

Repurposed Therapeutics, Inc. — full company profile →

Who can join

55 and older, any sex, with Motion Sickness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With Open-Label Follow-Up

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Scopolamine

Trials testing the same drug.

NCT07423923 — Representation of Spatiotemporal Information in Human Episodic Memory and Navigation · EARLY_PHASE1 · enrolling by invitation
NCT04999449 — Nebulizer Delivery of Intranasal Scopolamine · Phase 1 · completed
NCT04211961 — Scopolamine in Bipolar Depression · Phase 2 · completed
NCT03131050 — Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD · Phase 4 · completed
NCT02918266 — TAK-071 Scopolamine-Induced Cognitive Impairment Study · Phase 1 · terminated

Other recruiting trials for Motion Sickness

Currently open trials in the same condition.

NCT06892340 — Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation · NA · recruiting
NCT06138613 — Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness · Phase 3 · active not recruiting
NCT05622344 — StableEyes With Active Neurofeedback · NA · recruiting

Other Repurposed Therapeutics, Inc. trials

Trials by the same sponsor.

NCT05548270 — Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion · Phase 3 · completed
NCT04947423 — Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion · Phase 3 · completed
NCT04184115 — Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness · Phase 3 · completed
NCT03986905 — The Prevention and Treatment of Nausea Associated With Motion Sickness · Phase 3 · completed
NCT04219982 — DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness · Phase 2, PHASE3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03988530 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Repurposed Therapeutics, Inc.
Last refreshed: 6 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03988530.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing